Rheumatology Network's Top 5: April 23, 2021

April 23, 2021

Lana Dykes

Take 5 minutes to catch up on Rheumatology Network's highlights from the week ending April 23, 2021.

Patients With Inadequate Response to DMARDs at Higher Risk of Heart Attack

An analysis of medical data from a major database in Taiwan suggests an inadequate response to DMARD therapy among patients with rheumatoid arthritis was associated with increased risk of acute coronary syndrome.

Click the image to view the story.

Rebecca Manno, MD, MHS: ACR SOTA Clinical Symposium

Rheumatology Network sat down with Rebecca Manno, MD, MHS, to discuss the American College of Rheumatology State of the Art (ACR SOTA) Clinical Symposium, which ran from April 9-11.

Click the image to view the story.

Rheumatoid Arthritis Quiz: Principles of Treat-to-Target

A treat-to-target strategy is recommended by the American College of Rheumatology for managing rheumatoid arthritis patients over a non-targeted approach. Test your knowledge of the rationale for treat-to target and how it should be implemented in our quiz.

Click the image to view the story.

Rituximab May Be Linked to Severe COVID-19 Outcomes

Long-term administration of rituximab may be associated with more severe COVID-19 outcomes, including intensive care unit (ICU) admission or death, especially for those with other comorbidities.

Click the image to view the story.

Poor Social Determinants Linked to Worse Care and Outcomes for Patients With Lupus

While further studies are needed, the results indicate that resolving the SDoH issues, via programs like the iCMP, may decrease healthcare costs while equalizing care and outcomes for both patients with SLE and those with complex chronic conditions in general.

Click the image to view the story.